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Ionizing radiation (IR) is a powerful therapeutic modality for cancer, 
commonly used for its capacity to kill cancer cells. In this Frontiers 
Research Topic Book radiotherapy effects are re-visited, from the 
point of view of the host’s immune system (IS). An introductory 
article from Golden et al. (2012) examines the consequences of the 
many types of radiation-induced tumor cell death and how these 
coalesce to generate the key signals that define an immunogenic cell 
death (ICD). Cancer cells dying by ICD deliver a cascade of signals 
to the IS that culminates in the generation of anti-tumor T cells 
by providing a source of antigen for cross-presentation coupled 
with maturation signals to dendritic cells (DC). The ability of IR 
to induce an ICD is exploited by novel cancer therapies that have, 
for instance, shown the benefit of intra-tumoral injection of DC 
post-radiotherapy in preclinical models. Finkelstein and Fishman 
(2012) discuss this approach and the emergence of encouraging 
results from clinical pilot studies.
Burnette et al. (2012) provide an overview of the immunologi-
cal environment existing in tumor-bearing hosts, emphasizing the 
challenge of overcoming tolerance and immunosuppression to 
achieve tumor rejection. To overcome this barrier, combinations 
of IR with specific immunotherapies have been tested by sev-
eral labs and shown to be effective at eliciting robust anti-tumor 
immunity. One such strategy, discussed by Mason and Hunter 
(2012), is the combination of IR with intra-tumoral synthetic 
oligodeoxynucleotides such as CpG. The preclinical success of 
this combination was translated to the clinic where it has dem-
onstrated to induce rejection of the irradiated tumor as well as 
tumors outside the radiation field (abscopal effect). Another strat-
egy, which is in earlier stage of investigation but holds great poten-
tial, is nanovectorized radiotherapy discussed by Vanpouille-Box 
and Hindré (2012). Delivery of radionuclides using nanoparticles 
has the advantage of providing targeting specificity to the tumor 
as well as exploiting the intrinsic immunostimulatory properties 
of nanoparticles.
Importantly, IR effects exceed the classical cytocidal properties 
by also causing phenotypic changes in the fraction of surviving 
cells, markedly enhancing their susceptibility to T cell-mediated 
elimination. Kwilas et al. (2012) define these effects of IR as “immu-
nogenic modulation” and illustrate the examples of IR-induced 
Major Histocompatibility Complex antigens and death receptors, 
which improve tumor rejection by T cells adoptively transferred 
or activated by vaccination.
However, not all IR-induced modifications of the tumor and 
its microenvironment favor immune rejection. Chiang et al. 
(2012) provide novel evidence for accumulation of pro-tumor-
igenic M2 macrophages in areas of hypoxia present in irradiated 
tumors. Schaue et al. (2012) discuss the increase of regulatory T 
cells post-radiotherapy, potentially hindering the development 
of effective anti-tumor T cell responses. Intriguingly, the dose 
and fractionation of radiotherapy may play a role in modulating 
the expansion of effector versus regulatory T cells. This aspect 
is critically addressed by Demaria and Formenti (2012). Since 
much of the available preclinical data come from experiments 
testing single IR doses, further exploration of fractionated regi-
mens is warranted.
Overall, the book provides an overview of the available data and 
evolving concepts in support of a novel use of radiotherapy: that of 
an immune modulator and optimal partner for immunotherapy. 
While enthusiasm for the combination of IR and immunotherapy 
was enhanced by recent anecdotal reports in some cancer patients, 
much work remains to be done. Hopefully, the book will inspire 
more investigators to explore this new area, and encourage more 
discovery of the interaction of IR and immunity.
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